Canada markets open in 2 hours 57 minutes
  • S&P/TSX

    20,329.73
    -36.12 (-0.18%)
     
  • S&P 500

    4,402.66
    -20.49 (-0.46%)
     
  • DOW

    34,792.67
    -323.73 (-0.92%)
     
  • CAD/USD

    0.7991
    +0.0019 (+0.24%)
     
  • CRUDE OIL

    68.42
    +0.27 (+0.40%)
     
  • BTC-CAD

    47,647.20
    -39.45 (-0.08%)
     
  • CMC Crypto 200

    940.28
    +13.51 (+1.46%)
     
  • GOLD FUTURES

    1,815.00
    +0.50 (+0.03%)
     
  • RUSSELL 2000

    2,196.32
    -27.26 (-1.23%)
     
  • 10-Yr Bond

    1.1840
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,108.75
    +35.25 (+0.23%)
     
  • VOLATILITY

    17.51
    -0.53 (-2.94%)
     
  • FTSE

    7,119.49
    -4.37 (-0.06%)
     
  • NIKKEI 225

    27,728.12
    +144.04 (+0.52%)
     
  • CAD/EUR

    0.6745
    +0.0013 (+0.19%)
     

UPDATE 1-Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Adds details on agreement, background)

June 17 (Reuters) - Bristol-Myers Squibb Co and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug.

Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said.

They would jointly develop and market the drug, MORAb-202, in Asia, Europe, the United States and Canada.

Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer.

The drugmaker has been betting on sales of its Opdivo drug to treat such cancers, in a market currently dominated by Merck & Co's rival treatment, Keytruda.

Eisai's drug, MORAb-202, is being developed for the treatment of solid tumors, including ovarian, lung and breast cancers and is in the early stage of development.

Bristol-Myers will pay Eisai a royalty on sales outside of the collaboration territories, the companies said.

(Reporting by Amruta Khandekar; Editing by Vinay Dwivedi)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting